View ValuationRead-Gene 将来の成長Future 基準チェック /06現在、 Read-Geneの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Feb 24New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.4% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł68.9m market cap, or US$19.2m).Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (zł15m revenue, or US$4.3m). Market cap is less than US$100m (zł61.3m market cap, or US$17.2m).分析記事 • Jan 17Is Read-Gene (WSE:RDG) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).お知らせ • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (zł14m revenue, or US$3.9m). Market cap is less than US$100m (zł61.5m market cap, or US$16.7m).Buy Or Sell Opportunity • May 27Now 21% overvaluedOver the last 90 days, the stock has fallen 2.6% to zł4.11. The fair value is estimated to be zł3.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has declined by 68%.Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.分析記事 • Nov 27Read-Gene (WSE:RDG) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Aug 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł1.07m (down 49% from 2Q 2023). Net loss: zł333.0k (loss narrowed 53% from 2Q 2023).New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (zł11m revenue, or US$2.7m). Market cap is less than US$100m (zł74.3m market cap, or US$18.7m).分析記事 • Jul 17Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • Jun 05Read-Gene S.A., Annual General Meeting, Jun 26, 2024Read-Gene S.A., Annual General Meeting, Jun 26, 2024.Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.12m (up 41% from 1Q 2023). Net loss: zł534.9k (loss widened 20% from 1Q 2023).分析記事 • Feb 14Read-Gene (WSE:RDG) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Feb 13Full year 2023 earnings released: zł0.16 loss per share (vs zł0.018 profit in FY 2022)Full year 2023 results: zł0.16 loss per share (down from zł0.018 profit in FY 2022). Revenue: zł10.1m (up 39% from FY 2022). Net loss: zł1.85m (down zł2.06m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.お知らせ • Jan 20+ 4 more updatesRead-Gene S.A. to Report Fiscal Year 2023 Results on May 27, 2024Read-Gene S.A. announced that they will report fiscal year 2023 results at 8:30 AM, Central European Standard Time on May 27, 2024New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł8.5m revenue, or US$2.1m). Market cap is less than US$100m (zł56.4m market cap, or US$14.0m).New Risk • Aug 23New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (zł38.9m market cap, or US$9.47m). Minor Risk Revenue is less than US$5m (zł7.8m revenue, or US$1.9m).New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). Market cap is less than US$100m (zł43.4m market cap, or US$10.6m).Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł2.08m (flat on 2Q 2022). Net loss: zł711.9k (down 290% from profit in 2Q 2022).New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Revenue is less than US$5m (zł7.3m revenue, or US$1.8m). Market cap is less than US$100m (zł41.5m market cap, or US$10.2m).お知らせ • Jun 04Read-Gene S.A., Annual General Meeting, Jun 30, 2023Read-Gene S.A., Annual General Meeting, Jun 30, 2023, at 15:00 Central European Standard Time.Reported Earnings • Feb 12Full year 2022 earnings released: zł0.015 loss per share (vs zł0.003 profit in FY 2021)Full year 2022 results: zł0.015 loss per share (down from zł0.003 profit in FY 2021). Revenue: zł4.07m (down 37% from FY 2021). Net loss: zł178.6k (down zł216.4k from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.お知らせ • Jan 12+ 4 more updatesRead-Gene S.A. to Report Q3, 2023 Results on Nov 10, 2023Read-Gene S.A. announced that they will report Q3, 2023 results on Nov 10, 2023お知らせ • Jun 07Read-Gene S.A., Annual General Meeting, Jun 30, 2022Read-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.Reported Earnings • May 16First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł1.00m (down 13% from 1Q 2021). Net loss: zł305.8k (down zł342.8k from profit in 1Q 2021).Reported Earnings • Feb 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: zł6.45m (up 6.3% from FY 2020). Net income: zł342.5k (down 1.9% from FY 2020). Profit margin: 5.3% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł1.28m (down 14% from 3Q 2020). Net loss: zł608.1k (down 339% from profit in 3Q 2020).Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł1.35m (up 90% from 2Q 2020). Net income: zł112.8k (up zł535.4k from 2Q 2020). Profit margin: 8.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.Is New 90 Day High Low • Feb 11New 90-day high: zł4.06The company is up 77% from its price of zł2.30 on 13 November 2020. The Polish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 21% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: zł3.02The company is up 14% from its price of zł2.66 on 23 October 2020. The Polish market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 34% over the same period.お知らせ • Jan 13+ 3 more updatesRead-Gene S.A. to Report Q3, 2021 Results on Nov 14, 2021Read-Gene S.A. announced that they will report Q3, 2021 results on Nov 14, 2021分析記事 • Dec 17Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Read-Gene's (WSE:RDG) stock is up by a considerable 34% over the past three months. Given the company's impressive... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Read-Gene は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:RDG - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202516100N/A9/30/202515-122N/A6/30/202515055N/A3/31/202514-111N/A12/31/202413-122N/A9/30/202413000N/A6/30/202412-1-10N/A3/31/202411-1-1-1N/A12/31/202310-1-1-1N/A9/30/20239-1-1-1N/A6/30/20238-111N/A3/31/20238000N/A12/31/20227000N/A9/30/20227011N/A6/30/20227000N/A3/31/20226000N/A12/31/20216000N/A9/30/20217000N/A6/30/20217111N/A3/31/20216011N/A12/31/20206011N/A9/30/202062-1-1N/A6/30/202061-2-2N/A3/31/202071-2-2N/A12/31/201960-2-2N/A9/30/201980N/A-3N/A6/30/201980N/A-3N/A3/31/201971N/A-2N/A12/31/201871N/A0N/A9/30/20183-1N/A2N/A6/30/20184-1N/A2N/A3/31/201840N/A-2N/A12/31/201750N/A-1N/A9/30/20176-1N/A1N/A6/30/20175-1N/A0N/A3/31/201760N/A4N/A12/31/201650N/A0N/A9/30/201640N/A0N/A6/30/201640N/A2N/A3/31/20162-1N/A0N/A12/31/20152-1N/A-1N/A9/30/20151-1N/A-1N/A6/30/20151-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RDGの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RDGの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RDGの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RDGの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RDGの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RDGの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 23:31終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Read-Gene S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Feb 24New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.4% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł68.9m market cap, or US$19.2m).
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł0.069 (vs zł0.094 loss in FY 2024)Full year 2025 results: EPS: zł0.069 (up from zł0.094 loss in FY 2024). Revenue: zł15.6m (up 18% from FY 2024). Net income: zł808.3k (up zł1.92m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 11Read-Gene S.A. to Report Q4, 2025 Results on Feb 13, 2026Read-Gene S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Revenue is less than US$5m (zł15m revenue, or US$4.3m). Market cap is less than US$100m (zł61.3m market cap, or US$17.2m).
分析記事 • Jan 17Is Read-Gene (WSE:RDG) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: zł3.39m (up 1.6% from 3Q 2024). Net loss: zł237.4k (down 197% from profit in 3Q 2024).
お知らせ • Nov 12Read-Gene S.A. to Report Q3, 2025 Results on Nov 14, 2025Read-Gene S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł3.43m (up 16% from 2Q 2024). Net income: zł199.1k (up zł499.2k from 2Q 2024). Profit margin: 5.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (zł14m revenue, or US$3.9m). Market cap is less than US$100m (zł61.5m market cap, or US$16.7m).
Buy Or Sell Opportunity • May 27Now 21% overvaluedOver the last 90 days, the stock has fallen 2.6% to zł4.11. The fair value is estimated to be zł3.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has declined by 68%.
Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł1.47m (down 31% from 1Q 2024). Net loss: zł135.9k (loss narrowed 75% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 27Read-Gene (WSE:RDG) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Aug 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł1.07m (down 49% from 2Q 2023). Net loss: zł333.0k (loss narrowed 53% from 2Q 2023).
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (zł11m revenue, or US$2.7m). Market cap is less than US$100m (zł74.3m market cap, or US$18.7m).
分析記事 • Jul 17Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • Jun 05Read-Gene S.A., Annual General Meeting, Jun 26, 2024Read-Gene S.A., Annual General Meeting, Jun 26, 2024.
Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł2.12m (up 41% from 1Q 2023). Net loss: zł534.9k (loss widened 20% from 1Q 2023).
分析記事 • Feb 14Read-Gene (WSE:RDG) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Feb 13Full year 2023 earnings released: zł0.16 loss per share (vs zł0.018 profit in FY 2022)Full year 2023 results: zł0.16 loss per share (down from zł0.018 profit in FY 2022). Revenue: zł10.1m (up 39% from FY 2022). Net loss: zł1.85m (down zł2.06m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 20+ 4 more updatesRead-Gene S.A. to Report Fiscal Year 2023 Results on May 27, 2024Read-Gene S.A. announced that they will report fiscal year 2023 results at 8:30 AM, Central European Standard Time on May 27, 2024
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł8.5m revenue, or US$2.1m). Market cap is less than US$100m (zł56.4m market cap, or US$14.0m).
New Risk • Aug 23New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (zł38.9m market cap, or US$9.47m). Minor Risk Revenue is less than US$5m (zł7.8m revenue, or US$1.9m).
New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (zł7.8m revenue, or US$1.9m). Market cap is less than US$100m (zł43.4m market cap, or US$10.6m).
Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł2.08m (flat on 2Q 2022). Net loss: zł711.9k (down 290% from profit in 2Q 2022).
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Revenue is less than US$5m (zł7.3m revenue, or US$1.8m). Market cap is less than US$100m (zł41.5m market cap, or US$10.2m).
お知らせ • Jun 04Read-Gene S.A., Annual General Meeting, Jun 30, 2023Read-Gene S.A., Annual General Meeting, Jun 30, 2023, at 15:00 Central European Standard Time.
Reported Earnings • Feb 12Full year 2022 earnings released: zł0.015 loss per share (vs zł0.003 profit in FY 2021)Full year 2022 results: zł0.015 loss per share (down from zł0.003 profit in FY 2021). Revenue: zł4.07m (down 37% from FY 2021). Net loss: zł178.6k (down zł216.4k from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.
お知らせ • Jan 12+ 4 more updatesRead-Gene S.A. to Report Q3, 2023 Results on Nov 10, 2023Read-Gene S.A. announced that they will report Q3, 2023 results on Nov 10, 2023
お知らせ • Jun 07Read-Gene S.A., Annual General Meeting, Jun 30, 2022Read-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.
Reported Earnings • May 16First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł1.00m (down 13% from 1Q 2021). Net loss: zł305.8k (down zł342.8k from profit in 1Q 2021).
Reported Earnings • Feb 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: zł6.45m (up 6.3% from FY 2020). Net income: zł342.5k (down 1.9% from FY 2020). Profit margin: 5.3% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł1.28m (down 14% from 3Q 2020). Net loss: zł608.1k (down 339% from profit in 3Q 2020).
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł1.35m (up 90% from 2Q 2020). Net income: zł112.8k (up zł535.4k from 2Q 2020). Profit margin: 8.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.
Is New 90 Day High Low • Feb 11New 90-day high: zł4.06The company is up 77% from its price of zł2.30 on 13 November 2020. The Polish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 21% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: zł3.02The company is up 14% from its price of zł2.66 on 23 October 2020. The Polish market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 34% over the same period.
お知らせ • Jan 13+ 3 more updatesRead-Gene S.A. to Report Q3, 2021 Results on Nov 14, 2021Read-Gene S.A. announced that they will report Q3, 2021 results on Nov 14, 2021
分析記事 • Dec 17Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Read-Gene's (WSE:RDG) stock is up by a considerable 34% over the past three months. Given the company's impressive...